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Abstract 
The present study had three main objectives: to investigate the attitudes and concerns of general public and patients about 
pharmacogenetic testing, to analyse the concerns and attitudes of professionals (healthcare workers and non-healthcare 
workers) about these tests and to examine the role of pharmacists. We conducted a review of original research studies using a 
structured approach of the following databases: PubMed, Scopus and Kobson, from 2004 to June 2015. A total of 22 studies 
fulfilled our criteria for inclusion, being related to the attitudes, concerns and beliefs of professional and general public 
regarding pharmacogenetic testing. In general, both professional and general public support pharmacogenetic testing. The 
main concern was the relative lack of knowledge in this field. Recognising the role of pharmacists, who will represent the 
connection between other providers of pharmacogenetic services and patients, is an important aspect. Implementation of the 
scientific evidences would lead to a significant improvement of pharmacogenetic testing processes. 
 
Rezumat 
Studiu a avut trei obiective principale: analizarea atitudinii şi preocupărilor pacienţilor privind testarea farmacogenetică, 
analizarea preocupărilor şi atitudinii profesioniştilor (personal din domeniul sanitar şi din domenii cu specific nesanitar) legat de 
această testare și evaluarea rolului farmaciştilor. Am sumarizat rezultatele unor studii originale de cercetare, folosind o 
abordare organizată a următoarelor baze de date cu caracter ştiinţific: PubMed, Scopus şi Kobson, din 2004 până în iunie 2015. 
Un număr de 22 de studii au îndeplinit criteriile de selecţie deoarece conţinutul lor corela atitudinile, preocupările şi viziunile 
profesioniştilor din domeniu şi a publicului larg, cu privire la testarea farmacogenetică. În general, atât profesioniştii, cât şi 
populația susţin testarea farmacogenetică. Principala preocupare face referire la lipsa relativă de informaţii din acest domeniu și 
recunoaşterea rolului farmaciştilor de a reprezenta o punte de legătură între cei care oferă servicii în domeniul farmacogeneticii şi 
pacienţi. Implementarea noţiunilor ştiinţifice va conduce la dezvoltarea semnificativă a procesului de testare 
farmacogenetică. 
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Introduction 
Pharmacogenetics is a relatively young scientific 
discipline having its beginning in 1902, thanks to 
the English physician Garrod Archibald who noted 
that the way in which we react to therapy is due to 
“innate errors of metabolism” [1]. The first pharmaco-
genetic study was conducted in 1932 with a chemical 
compound phenylthiocarbamide, which confirmed 
that chemical compounds react differently, depending 
on the genetic characteristics of individuals. Friedrich 
Vogel has first used this term, presenting it as 
"clinically important genetic variation in response 
to drugs" and thus defined this comprehensive 
discipline [2]. After completion of the “Human 
Genome Project” in 2001 and the cognition of the 
human genome, the complexity of the biochemical 
pathways and the interaction of genes and their 
products, the term “pharmacogenomics” was introduced 
[3]. According to the World Health Organization, 
genetics studies the structure and function of 
individual genes, while genomics considers the entire 
genome, the relationship of genes and their influence 
on the body. For many, they remain synonymous to 
this day. But whichever the discipline, the objective 
is identical, and that is the individualization of 
therapy based on specific person genotype [4,5]. 
Polymorphism: the impact on pharmacokinetics and 
pharmacodynamics of drugs 
The Food and Drug Administration (FDA) states 
that pharmacogenomics is an opportunity to identify 
new biomarkers that will accelerate the process of 
drug development. So far there are more than 198 
agents with their pharmacogenetic findings included 
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in the FDA-approved labelling medicines. Drug 
labelling may contain information on genomic bio-
markers and can describe: drug exposure and 
variability of clinical response; risk for adverse events; 
genotype-specific assessment; mechanisms of drug 
action; polymorphic drug target and disposition genes 
[6]. 
Polymorphism for enzymes involved in the metabolism 
of drugs, carriers, and/or drug's site of action can 
change the response to the drug and lead to un-
wanted reactions and treatment failure. So far, poly-
morphism is identified in more than 20 enzymes 
involved in the metabolism of drugs. In some there 
are differences in frequency while in others specific 
phenotypic consequences are critical determinants of 
treatment outcomes. The most important genetic poly-
morphic enzymes are hepatic cytochrome P450 enzymes 
such as CYP1A2, CYP2C9, CYP2C19, CYP2D6, 
CYP3A4. They are responsible for the metabolism 
of most drugs, in its first phase. While in the second 
phase of metabolism, genetic polymorphic enzymes 
are UGT1A1 and TMPT. Detailed presentation of 
these enzymes with their substrates and functional 
consequences is shown in Table I [7, 8]. 
Table I 
Polymorphism for enzymes involved in the metabolism of drugs [adapted from 8] 
DPYD: Dihydropyrimidinedehydrogenase, UGT1A1: uridinediphosphate-glucuronosyltransferase TPMT: Thiopurine S-methyl transferase 
 
Besides enzymes involved in metabolism and 
pharmacological site of action may exhibit genetic 
polymorphism, and thus influence the response to 
the drug. The most common pharmacodynamic poly-
morphisms those are associated with the site of 
action leads to cardiac arrhythmia (mutation sodium 
and potassium channels), heart failure (mutation β2-
adrenoreceptor agonist), asthma (mutation β2-adreno-
receptor agonist and a promoter 5-lipoxygenase), 
tuberculosis, depression (serotonin transporter mutation). 
So, polymorphism occurs both in genes encoding 
enzymes of metabolism, receptors and channels as 
well as in the genes responsible for the intracellular 
signal transduction [9, 10, 34]. 
Reply of individual may be different depending on 
whether they have or not genetic variations, and in 
this regard can be expected absence, excessive or 
inadequate response to a particular drug or group of 
drugs. Detection of genotype-phenotype correlation 
in the process of drug development, and demonstrate 
clinical validity and utility of the course of research 
will improve current drug therapy, ensure the 
achievement of better outcomes and certainly improve 
clinical practice. [13] Research conducted in the UK 
showed that the cause of admission to hospital due 
to adverse drug reactions had an incidence of 6.5%. 
In the United States, 6.7% of all hospitalizations are 
due to serious adverse events, causing deaths in 
0.37% of the cases. In this regard it is acknowledged 
the role of pharmacogenetic tests that will reduce 
adverse reactions to drugs, and improve the efficiency 
and safety of drugs [8]. 
The application of pharmacogenetics is not only for the 
treatment of diseases, but also for the development of 
new medicines and other products, such as vaccines. 
This technology has potential applications in the 
public vaccination programs for disease prevention, 
which would lead to the identification of the vaccine 
for small sub-populations genetically. The ethical 
reason for the application of pharmacogenetics in 
this case would be an extremely strong one, given 
that these vaccines do not only provide the well-
being of the individual, but also for the benefit of 
the general population. 
In recent years, more and more clinical trials 
include collecting and analysing DNA for approval 
of new drugs. This may involve testing samples 
taken from participants in the early stages of 
clinical testing in order to identify the pharmaco-
genetic effects in response to treatment, or testing 
patients during the phase of monitoring and super-
vision, if there are adverse reactions to drugs. These 
requirements are set by regulatory bodies, which 
deal with providing optimal conditions for the safe 
use of new drugs. 
Pharmacogenetic testing offers many benefits for 
the patient: reducing of adverse effects by adjusting 
the appropriate drug or proper dose for each patient; 
probabilistic evaluation of efficacy; reference to the 
relevant therapeutic alternative that will be equally 
or more useful for the patient; reducing the time of 
Phase I metabolism            Functional consequences of polymorphism             Substrates for enzymes 
CYP1A2 High inducibility Caffeine, lidocaine, paracetamol 
CYP2C9  Reduced activity                       Celecoxib, diclofenac, fluvastatin, ibuprofen, 
clopidogrel, losartan 
CYP2C19  Deficiency activity Diazepam, omeprazole, propranolol 
CYP2D6   Deficiency activity and extremely high activity-
induced gene duplication                         
Ajmaline, fluoxetine, haloperidol, 
metoprolol, mexiletine, propafenone 
CYP3A4   Slightly decreased activity              Erythromycin, nifedipine, paclitaxel  
Phase II metabolism   
UGT1A1 Reduced activity                              Irinotecan 
TMPT  Deficiency activity                           Azathioprine, 6-Mercaptopurine 
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treatment; detection of absolute or relative contra-
indications for prescribing medicines; reducing the 
cost of treatment by avoiding ineffective or harmful 
drugs; preventing unnecessary patient suffering. Data 
about the significant negative consequences of the 
application of pharmacogenetic testing in clinical 
practice is unknown until now [11, 12]. 
Given the great interest in this area that is in expansion 
we want to analyse the attitudes of both, professionals 
and general public, regarding pharmacogenetic testing 
and their opinion on how to deliver these services 
to patients in the healthcare system. We set three 
main objectives: to investigate the concerns’ and 
attitudes of professionals (healthcare and non-
healthcare workers) about pharmacogenetic testing, to 
analyse the perspective and attitudes of the general 
public about pharmacogenetic testing and to examine 
the role of pharmacists in pharmacogenetic testing. 
 
Materials and Methods 
A structured search of the following databases was 
performed to retrieve published papers addressing 
professional and general public perspective on 
pharmacogenetic testing: PubMed, Kobson and Scopus. 
The electronic database search was carried out in 
the period from 2004 to 2015, and 906 articles were 
identified. Keywords that we used were: pharmacogenetic 
testing and opinions and general public or health-
care professionals or pharmacists. All articles with 
full text in English or Serbian language were taken 
into account, if they meet all necessary criteria. Two 
investigators (ML and DK) independently performed 
the literature search and the collection of publications 
and gave the assessment of the requirements for 
inclusion in the analysis of publications. Inclusion 
criteria were: original papers that were oriented to 
attitudes and concerns of general public or patients 
or professionals toward pharmacogenetic testing, 
papers oriented to pharmacists and their role in the 
pharmacogenetic testing services. After a brief 
review of abstracts and results, some articles were 
eliminated because they were not related to pharmaco-
genetic testing, case reports/reviews/editorials/ 
abstracts/qualitative studies and available only as 
abstracts. Standardized data collection tool was used 
to characterize each study taken into consideration. 
 
Results and Discussion 
In the first search we identified 906 citations and 
conducted extraction following the strategy presented 
in Figure 1. First, we removed 173 duplicates and 
475 studies that were not related to the pharmaco-
genetic testing, 150 reviews and editorials, 29 review 
articles and 48 abstracts. A total of 875 citations 
were excluded. After the full-text review we excluded 
9 studies that did not relate to the attitudes and 
concerns of pharmacogenetic testing, did not have 
the full article available or did not refer to the role 
of pharmacists in pharmacogenetic testing. After 
the final selection, 22 studies fulfilled the inclusion 
criteria [11, 14-36]. Distribution of articles by 
publication year was presented at Figure 2. Articles 
were dominantly from the 2011 and 2012 years 
(36.36%). 
 
 
Figure 1. 
Structured search strategy 
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Figure 2. 
Number of publications identified by years (analysed by the year of publication) 
 
Geographical distribution of the journals shows that 
studies were mostly published in international journals 
19 (86.36%) and 13 American journals (64%). 
Among the 22 analysed studies [11, 13-33], only 2 
(9.09%) referred to attitudes and concerns of the 
general public, patients 7 (31.82%) and professionals 5 
(22.73%), while a quarter of them 40.91% (9 papers) 
examined and presented the role of pharmacists in 
pharmacogenetic testing. 
We identified several attitudes and concerns of 
professionals and general public about pharmacogenetics 
testing. We used the term general public only to refer 
to non-patients. These attitudes are both positive 
and negative, and they vary depending on age and 
the existence of previous experiences with adverse 
events to medicines, as well as the origin of the 
respondents. Concerns are related to the privacy of 
their results and the lack of knowledge about the 
pharmacogenetic testing services (Table II). There 
were the differences of opinion of the general public 
about the additional information and their impact 
on psychological health. Professionals, divided as 
healthcare professionals and other experts involved 
in the provision of pharmacogenetic testing services 
generally support the testing and have a willingness to 
participate. Pharmacists as the object of our interest, 
were considered separately. Our next objective was 
to determine if the role of pharmacists in providing 
these services is recognized and whether it is negative 
or positive. 
Table II 
Summarized results about attitudes and concerns of professionals and general public regarding pharmacogenetic 
testing 
 General public Patients Healthcare 
workers 
Non-healthcare 
workers 
Pharmacists 
Attitudes      
Approve 
pharmacogenetic 
testing 
Depending on the age 
and previous negative 
experience with adverse 
reactions to drugs 
Expressed 
willingness to 
undergo testing  
Think that patient 
have benefit from 
pharmacogenetic 
testing 
Have a positive 
opinion 
Great interest in 
community pharmacy 
for testing and 
counselling patients  
Healthcare 
professionals 
explain the test 
and result 
Consider this as 
necessary 
Expect a good 
explanation of the 
pre-trained  
healthcare 
professionals  
Believe that they 
should participate 
Think that they 
should be 
involved in the 
interpretation of 
test results 
Believe that pharmaco-
genomics will have a 
major impact on their 
role in improving the 
patient's health  
Role of 
pharmacists in 
pharmacogenetic 
testing 
Recognize the role 
of pharmacists 
No preference 
which healthcare 
professionals will 
be involved 
Find that they have 
a major role 
Want to cooperate 
with pharmacists 
See themselves in this 
role especially in 
counselling patients 
Concerns      
Lack of 
knowledge about 
pharmacogenetic 
testing 
Concerned about the 
lack of knowledge 
in this field 
Expect timely and 
accurate 
information but 
they are not sure 
about that  
 
Find that they need 
additional education 
and 80% physicians 
stated that they had 
never recommended 
testing  
Considered they 
have sufficient 
knowledge about 
pharmacokinetics 
and pharmaco-
dynamics of drugs  
Most pharmacists 
believe that their 
advice is poor or even 
very poor and 
highlight the need for 
further education 
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Additional 
information for 
respondents 
While some think 
that receiving 
unwanted test 
results adversely 
affect their 
psychological 
health, others see 
benefit from them  
They are 
concerned about 
acceptance of 
these information  
The majority of 
physicians agreed to 
reveal helpful 
information about 
testing to patients 
Geneticists 
believed that it 
depends on the 
“case by case”  
Believe that through 
genetic counselling 
can be psychological 
support to patients 
 
Results about summarizing the attitudes and concerns 
of patients and the general public 
Attitudes 
As for the attitudes of the general public on 
pharmacogenetic testing, most of them justified and 
expressed willingness to undergo testing. Specifically, 
younger people showed more interest in pharmaco-
genetic testing. This is the case with respondents 
who have had previous negative experiences with 
adverse reactions to drugs. 
Patients as most users of these services, generally, 
have a positive attitude about pharmacogenetic 
testing. It was found that patients who have had 
previous experiences with adverse reactions to drugs 
and those who are afraid of the potential in future 
show interest and provide greater support for this 
service [15, 36]. 
Patients expect that healthcare workers who provide 
pharmacogenetic services should explain the test 
and interpret the implications of the regulation [16]. 
In the UK conducted studies showing that patients 
do not have a preference in terms that health 
workers should provide pharmacogenetic services 
but they give priority to timely and accurate 
information about the usefulness of testing and its 
impact on their health [17] as well as a good 
explanation of the pre- trained health workers [16].  
When asked which health workers would they hold 
responsible for distributing and storing the results 
of pharmacogenetic testing for their re-use if 
needed, patients have declared that they would feel 
very safe to share their results with other doctors in 
their healthcare. Regarding pharmacists, patients also 
agreed that they should be included in distributing 
and storing the results of pharmacogenetic testing 
for their re-use, but patients have less confidence in 
pharmacists than in doctors [14]. 
Concerns 
Opinions were divided among general public when 
considered the issue of additional information that 
the respondents received. While some felt that the 
communication of adverse test results in detrimental 
effects on their psychological health, others pointed 
out that it will not endanger their health or any 
decision of pharmacogenetic testing. Again, public 
attitudes toward pharmacogenetic testing depends 
on the country of origin. For example, in Poland, 
the participants unanimously supported the testing, 
while respondents from the United Kingdom and 
the United States showed a dose of reservation [18]. 
As one of the problems patients highlighted a general 
lack of knowledge of pharmacogenetic testing [19]. 
Also, as major obstacles, the patients stand out the 
privacy issues regarding their genetic information 
and test results and the costs of testing and 
insurance coverage [15, 20]. 
Results about the attitudes and concerns of professionals 
(healthcare and non-healthcare workers) 
Attitudes 
Healthcare workers believe that patients have benefit 
from pharmacogenetic testing. They see themselves 
in the major role with the mandatory participation 
[21]. Genetic counsellors considered that they should 
be involved in the interpretation of test results and 
want to cooperate with pharmacists [22]. 
The survey of physicians and geneticists about extra 
information has led to the following results: the 
majority of physicians agreed to reveal helpful 
information about testing patients while geneticists 
believe that it depends on the “case by case” [23]. 
Concerns 
Some studies have stated that the lack of knowledge 
and clinical evidence are the greatest barriers to the 
implementation of this approach [11]. 80% of 
physicians stated that they had never recommended 
testing, although they are considered as primary 
providers of these services [21]. Problems cited were 
the influence of time needed for pharmacogenetic 
testing that delays treatment and storage of test 
results in medical records [23]. 
It was found that service providers used to limit 
patient access to information in connection with 
pharmacogenetic testing, example of this is the test for 
trastuzumab, and the reason is to avoid disappointment 
if the patient is not “appropriate” for therapy [24]. 
Attitudes and concerns of pharmacists 
It was determined that most pharmacists have a 
positive opinion about the perceived benefits of 
pharmacogenetic testing, and agree that part of their 
role should be patient counselling regarding information 
on pharmacogenetic testing, in particular for "one 
to one" contact between patients and pharmacists. 
There is a great interest of pharmacists in community 
pharmacy for testing and willingness to consult 
patients about the results.  
When pharmacists were questioned about their views 
on the ethical implications of genetic testing, most of 
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them showed concern about insurance companies 
which can use the results of pharmacogenetic testing to 
deny health coverage. Genetic Information Non-
discrimination Act (GINA) adopted on 21 May 2008 
in the United States prohibits discrimination by 
health insurers and employers based on genetic 
information, including the results of genetic testing 
of patients and their families. However, the 
impression is that healthcare providers are not 
familiar with it, and therefore there is concern about 
the denial of health coverage. Future training for 
pharmacists should focus on ethical issues in order 
to ensure feasibility in clinical practice [25]. 
Results about the role of pharmacists in pharmaco-
genetic testing 
Pharmacogenetics provides a unique opportunity 
for pharmacists who will be the connection between 
other providers of pharmacogenetic services and 
patients. Pharmacists can use their knowledge of 
pharmacokinetics and pharmacodynamics, and thus 
help doctors to choose the right drug, the correct 
dose and enable avoidance of adverse effects. They 
are also involved in patient education, recommending 
testing to patients and reporting on the results of 
tests. However, their knowledge of genetics is not 
enough, which should include genetic counsellors, 
who will deal with specific issues regarding testing 
[22]. There are numerous models of providing 
pharmacogenetic services by pharmacists. St. Jude 
Children's Hospital in Nashville, TN (USA) has 
implemented a clinical pharmacogenetic service, 
where the clinical pharmacists have an active role 
in reviewing the test results and in recommending 
the selection of therapy [26]. Also, their role in 
providing pharmacogenetic testing in the framework 
of public pharmacies is well-researched and analysed. 
Pharmacists in public pharmacies are an integral 
part of patientcare through the Medication Therapy 
Management (MTM). Pharmacists have developed 
a relationship with patients and they are ready to 
provide clinical services in response to the results 
of pharmacogenetic testing. This will only lead to 
an extension of their current roles towards an 
insight into the results and recommendation of their 
opinion. In community pharmacies this project would 
not have succeeded without the establishment of 
relations with associates. Each collaborator fills an 
important role and brings significant resources, 
expertise and experience, which should be taken 
into account when establishing pharmacogenetic 
services [27]. 
Genetic counselling aims to facilitate people making 
decisions about testing, to ensure a common under-
standing of genetic variation, and to provide 
psychological support after the test [28]. Bearing in 
mind that in many countries it requires counselling 
patients by pharmacists, this role is expected in the 
process of genetic counselling also. 
Attitudes 
Pharmacists think that pharmacogenomics will have 
a major impact on their role in improving the 
patient's health [29]. In North Carolina (USA) were 
observed favourable attitudes of pharmacists regarding 
pharmacogenetic testing and the existence of a desire 
to learn more about this impressive discipline [30]. 
In Australia it is conducted a research among 
pharmacists, where counselling is seen as one of the 
areas of pharmacy practice that pharmacogenetics 
will have the greatest impact on. The attitudes of 
pharmacists in terms of counselling have led to the 
following statements: pharmacogenetics could lead 
to an increased demand for consulting and therefore 
requiring a longer time spent with the patient; 
regarding the complexity of counselling, pharmaco-
genetics improve the ability of the pharmacist in 
counselling patients; pharmacogenetic information 
will assist in optimizing therapies; the impact of 
pharmacogenetics to the pharmaceutical profession 
would depend on the availability of test results and 
the patient's willingness to disclose details about 
their genetic profile. 
Concerns 
In order to ensure appropriate high standards of 
counselling and pharmaceutical care there is a need 
for future education and understanding of pharmaco-
genetics by pharmacists. The proposal is that the 
training is carried out within the framework of the 
faculty studies, as well as seminars and workshops 
which are an integral part of their continuing 
professional development [29].  
It is proposed a partnership of genetic counsellors 
and pharmacists that will enable the provision of 
comprehensive services to physicians and patients 
about the proper use of tests based on known 
evidence [22]. There were identified certain barriers 
in this approach. [31] Those are relating to: 
preparing genetic counsellors and pharmacists to 
provide pharmacogenetics testing services [32], 
limitation of the workforce genetic counsellor [33], 
benefits of patients and professionals [14], tests 
readiness [34] and reimbursement [35]. 
With the advent of pharmacogenetics begins the era 
of personalized medicine, which will identify the 
best drug for a given patient, and also the most 
effective and safest dose from the start of drug 
administration. This approach to the treatment of 
diseases is promising compared to the traditional 
“one size fits all” approach. With the discovery of 
the entire human genome public and healthcare 
professionals expect that all doubts and failures to 
be avoided. Expectations are high and it is hoped 
that each patient will possess a card with a 
microchip that will contain its genetic information 
in order to provide highly individualized therapy, 
being acknowledged the great advances in 3D 
printing techniques applied in drugs manufacturing 
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[12, 13]. Legislation on this matter has certain 
characteristics: apply to tests in order to achieve certain 
health conditions, protect the autonomy, integrity 
and privacy of people tested, sets the requirements 
for the process of genetic counselling and 
mechanisms in order to preserve the quality of the 
tests. Laws in Germany, Sweden and Switzerland 
allow testing under certain conditions in terms of 
insurance. These countries allow the use of genetic 
information for risk assessment if the amount of 
insurance exceeds a specified level, while Austria, 
France and Portugal explicitly forbid using genetic 
information in the context of insurance. In the 
absence of specific laws relating to the field of 
genetics, general legal framework covering the area 
of health refers to the doctor-patient relationship, 
professional ethics, compliance, health performance, 
privacy and confidentiality, and may apply also to 
genetic tests. The role of regulations is to facilitate 
the practice and interests of the community by 
setting appropriate conditions and framework for 
conducting genetic activity and it serves to ensure 
public confidence [20]. 
Our findings suggest that generally, professionals 
and general public support pharmacogenetic testing. 
Increasing the efficacy of the drug, avoiding side 
effects and personalized care are the most frequently 
cited reasons for approval. However, it is high-
lighted the relative lack of knowledge in the field of 
pharmacogenetics, which was the main cause for 
concern. General public has shown concerns about 
privacy and the possibility of misuse of genetic 
information by insurance companies. Similar concerns 
are shared by healthcare and non-healthcare workers. 
Although general public has shown a desire to 
receive the test results, healthcare providers do not 
fully agree with that, the reason is the potential 
psychological harm to the patient. It is necessary to 
do research on under-represented minority groups 
in order to identify specific obstacles. 
As for the role of pharmacists, certainly, it is necessary 
to engage in pharmacogenetic testing, because their 
knowledge and skills contribute to the process with 
the ultimate goal of improving public health. There are 
several models and different strategies for delivering 
pharmacogenetic testing, but whether healthcare 
workers will be involved, and there will be a 
collaborative model, it depends on the type of test 
to be used, the connection with the complexity of 
information and the implications for the patient's 
health. 
Limitations 
We would like to point out several limitations of 
this research: it was searched a relatively small 
number of databases to find full papers. Keywords 
that were used may not be comprehensive for finding 
relevant work. Then, the power of this study was 
limited by the short time frame for search and the 
access to some full papers 
 
Conclusions 
We performed a literature review with a structured 
approach to assess the attitudes and concerns of 
professionals (healthcare and non-healthcare workers), 
general public and patients regarding pharmacogenetic 
testing. The common theme of all stakeholders was 
the support of pharmacogenetic testing and the 
relative lack of knowledge, while concern about 
privacy, cost and the spread of the test results 
differed among the groups. The role of pharmacists 
is recognized, particularly in the process of genetic 
counselling. Pharmacogenetic testing techniques 
will develop, requiring more guidance in this area. 
Awareness of these issues will help to facilitate the 
implementation of pharmacogenetic tests by pharmacists 
and other professionals, if the promise of personalized 
medicine is completed and it is implemented with 
all its potential. 
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